3.43
Schlusskurs vom Vortag:
$3.43
Offen:
$3.43
24-Stunden-Volumen:
383.57K
Relative Volume:
0.86
Marktkapitalisierung:
$293.54M
Einnahmen:
$351.37M
Nettoeinkommen (Verlust:
$-174.01M
KGV:
-1.657
EPS:
-2.07
Netto-Cashflow:
$-126.94M
1W Leistung:
-3.92%
1M Leistung:
+5.54%
6M Leistung:
+9.94%
1J Leistung:
-9.02%
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Firmenname
Atea Pharmaceuticals Inc
Sektor
Branche
Telefon
857-204-8109
Adresse
225 FRANKLIN STREET, BOSTON
Vergleichen Sie AVIR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
AVIR
Atea Pharmaceuticals Inc
|
3.43 | 305.52M | 351.37M | -174.01M | -126.94M | -2.07 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-08-13 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2023-08-10 | Herabstufung | JP Morgan | Neutral → Underweight |
2022-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2021-11-18 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2021-10-20 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-10-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-11-25 | Eingeleitet | Evercore ISI | Outperform |
2020-11-24 | Eingeleitet | JP Morgan | Overweight |
2020-11-24 | Eingeleitet | Morgan Stanley | Overweight |
2020-11-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Atea Pharmaceuticals Inc Aktie (AVIR) Neueste Nachrichten
Atea Pharmaceuticals Inc. Stock Analysis and ForecastTurbocharged investment results - jammulinksnews.com
What analysts say about Atea Pharmaceuticals Inc. stockHigh-profit capital plays - Autocar Professional
What drives Atea Pharmaceuticals Inc. stock priceRapid profit acceleration - jammulinksnews.com
Is Atea Pharmaceuticals Inc. a good long term investmentFree Investment Community - jammulinksnews.com
Why Atea Pharmaceuticals Inc. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser
What makes Atea Pharmaceuticals Inc. stock price move sharplyFree Stock Portfolio Optimization - Newser
How Atea Pharmaceuticals Inc. stock performs during market volatilityFree Stock Movement Tracking - Newser
Atea Pharmaceuticals announces continued advancement of global Phase 3 HCV program - European AIDS Treatment Group
Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing - Bain Capital
New Hepatitis C Treatment Could Slash Therapy Time to 8 Weeks as Global Phase 3 Trial Advances - Stock Titan
Atea Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
Here's Why We're Not At All Concerned With Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation - Yahoo Finance
Bank of America Corp DE Boosts Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Millennium Management LLC Invests $75,000 in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Squarepoint Ops LLC Buys 35,053 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Two Sigma Investments LP - Defense World
Jane Street Group LLC Decreases Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Public Employees Retirement System of Ohio Trims Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Ameriprise Financial Inc. Sells 11,900 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
ProShare Advisors LLC Buys 6,163 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
BNP Paribas Financial Markets Buys New Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Northern Trust Corp Boosts Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
D. E. Shaw & Co. Inc. Purchases 62,505 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Wall Street Zen Upgrades Atea Pharmaceuticals (NASDAQ:AVIR) to “Hold” - Defense World
Price T Rowe Associates Inc. MD Purchases 3,882 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Q2 EPS Forecast for Atea Pharmaceuticals Reduced by Analyst - Defense World
Dimensional Fund Advisors LP Has $3.27 Million Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Transcript : Atea Pharmaceuticals, Inc.Special Call - marketscreener.com
Atea Pharmaceuticals Advances HCV Treatment Trials - TipRanks
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Finanzdaten der Atea Pharmaceuticals Inc-Aktie (AVIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):